{
    "clinical_study": {
        "@rank": "84018", 
        "acronym": "Kagami_SDS", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Group 1 (placebo group) is treated by Anaesthesiologist"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed as a multi-centre, randomised, parallel-group, placebo-controlled,\n      phase III confirmatory study.  The study will be partially double-blinded: the comparison\n      between Group 1 (placebo group) and Group 2 (ICI35,868 without EES0000645/A) will be carried\n      out in double-blind, but the comparison between Group 1 (placebo group) and Group 3\n      (ICI35,868 with EES0000645/A) will be carried out in single-blind.\n\n      The efficacy and safety of ICI35,868 with and without EES0000645/A for the sedation to be\n      moderate for a diagnostic gastrointestinal endoscopy and gastrointestinal endoscopic\n      polypectomy will be evaluated."
        }, 
        "brief_title": "Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.Provision of written informed consent prior to any study-related procedures/examinations\n        2.Aged 20 years and older 3.Subjects who are planned to undergo a non-emergent EGD or\n        colonoscopy, including gastrointestinal endoscopic polypectomy that shall be completed\n        within 1 hour (excluding the endoscopic submucosal dissection and ultrasonic endoscope,\n        pernasal endoscope, etc.). Exclusion Criteria:\n\n          1. involvement in the planning and/or conduct of the study (applies to both sponsor's\n             employees and/or staffs at the study site)\n\n          2. Subjects who underwent a endoscopic procedure under ICI35,868 (propofol)\n             administration within 1 year.\n\n          3. Participation in another clinical study with an investigational product within 4\n             weeks prior to randomisation.\n\n          4. Baseline (Visit 1) of blood oxygen saturation (SpO2)<90% (room air)\n\n          5. ASA III, IV, V and VI ; Subject with serious disease of cardiovascular, respiratory,\n             renal, liver, pancreatic or endocrine function."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "279", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961349", 
            "org_study_id": "D0092C00002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1", 
                "description": "Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)", 
                "intervention_name": "Intralipid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "Treated by Anaesthesiologist", 
                "intervention_name": "ICI35,868 (Diprivan)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group 3", 
                "description": "Treated by Endoscopist with EES0000645/A(SDS)", 
                "intervention_name": "ICI35,868 (Diprivan) + EES0000645/A (SDS)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Propofol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "sedation, propofol, gastrointestinal endoscopy", 
        "lastchanged_date": "April 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Moriya-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III Confirmatory Study to Assess Efficacy and Safety of the Moderate Sedation of ICI35,868 With and Without EES0000645/A on Gastrointestinal Endoscopy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceutical and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The target sedation is defined to be Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of 2 to 4 for \u226550% of all MOAA/S measurements", 
            "measure": "Achievement of \"target sedation\" using MOAA/S score", 
            "safety_issue": "No", 
            "time_frame": "During procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961349"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate subject satisfaction with sedation using Patient Satisfaction with Sedation Instrument (PSSI) questionnaire.", 
                "measure": "Subject satisfaction (PSSI questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "Decreased SpO2 (degree of saturation <90% for \u2265 15 seconds)", 
                "measure": "Respiratory episodes", 
                "safety_issue": "Yes", 
                "time_frame": "5 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "Johnson & Johnson", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}